Prakash Achaary

MMS Holdings Executive Michelle Gayari Joins Advisory Board of International Nonprofit

MMS Holdings Executive Michelle Gayari Joins Advisory Board of International Nonprofit

CANTON, Mich. (October 23, 2019) – MMS Holdings – an award-winning, data-focused CRO – announced today that its Executive Director of Global Operations Michelle Gayari has joined the advisory board for the international 501(c)(3) charity Together Educating All Children in Hospitals (TEACH). As its sole board member in the state of Michigan, Gayari will provide leadership, guidance, and fundraising support to help in bringing exciting, hands-on educational programs to children in hospitals.

MMS Holdings Launches New Time-Saving Application to Automatically Perform Quality Control and Style Checks for Medical Writers

MMS Holdings Launches New Time-Saving Application to Automatically Perform Quality Control and Style Checks for Medical Writers

CANTON, Mich. (June 27, 2019) – MMS announced today the launch of Automatiqc™ (pronounced: automatic). Automatiqc is a new cloud-based application that automatically performs quality control (QC) and style checks for medical writing, pharmacovigilance, clinical trial transparency, and other types of documents in the pharmaceutical, biotechnology, and medical device industries.

Dr. Mike Poole Joins the Board of Scientific Advisors at Top Global CRO MMS Holdings

Dr. Mike Poole biomatics capital mms holdings bill and melinda gates foundation astrazeneca pfizer wyeth link medicine hypinion cro services vendor consultant clinical development plans cdp nda inda fda filing

SEATTLE (May 23, 2019) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today the addition of Dr. Mike Poole, MD, FACP to its board of scientific advisors. Currently a venture partner at Biomatics Capital, Inc., Dr. Poole has more than 25 years of experience in the pharmaceutical industry, most recently having led external investments in the Office of the President for Global Health at the Bill and Melinda Gates Foundation.

BREAKING NEWS: MMS partners with MIT Julia Lab and University of Maryland to create the Health Analytics Collective

Health Analytics Collective MIT UMB MMS Holdings Julia Computing

by MIT news, January 25, 2019
The timeline to market a new drug or medical device, from the point of discovery to U.S. Food and Drug Administration approval, can stretch to a decade. By pooling its industry experience and technology, a new health research supergroup led by the Julia Lab within the MIT Computer Science and Artificial Intelligence Laboratory aims to significantly shorten the approval process for pharmaceutical and health care groups.